AAA
KPTI icon

Affinity Asset Advisors’s Karyopharm Therapeutics KPTI Stock Holding History

Affinity Asset Advisors’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-157,600
Closed -$1.03M – 107
2025
Q3 		$1.03M Buy
157,600
+100
+0.1% +$538 0.09% 84
2025
Q2 		$679K Buy
+157,500
New +$773K 0.09% 75

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Affinity Asset Advisors's KPTI Position: Q1 2026 in Review

Affinity Asset Advisors reduced its Karyopharm Therapeutics (KPTI) stake by 44% in Q1 2026, selling an estimated $2.97M and leaving 500,000 shares worth $2.79M. The position accounts for 0.14% of the portfolio, ranked #86.

Affinity Asset Advisors first reported a position in KPTI in Q4 2022 and has held it in 4 quarters since. The position peaked at $6.55M in Q4 2025. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Affinity Asset Advisors held 500,000 shares of Karyopharm Therapeutics worth $2.79M as of Q1 2026.
  • Affinity Asset Advisors sold 389,575 Karyopharm Therapeutics shares in Q1 2026, an estimated $2.97M.
  • Karyopharm Therapeutics made up 0.14% of Affinity Asset Advisors's portfolio in Q1 2026, its #86 holding.
  • Affinity Asset Advisors first reported a position in Karyopharm Therapeutics in Q4 2022 and has held it in 4 quarters since.
  • Affinity Asset Advisors's Karyopharm Therapeutics position peaked at $6.55M in Q4 2025.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.